Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
January 2025
The global infectious disease vaccines market size is calculated at USD 38.83 billion in 2025 and is forecasted to reach around USD 72.40 billion by 2034, accelerating at a CAGR of 7.17% from 2025 to 2034. The Asia Pacific market size surpassed USD 12.61 billion in 2024 and is expanding at a CAGR of 7.23% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global infectious disease vaccines market size accounted for USD 36.25 billion in 2024 and is predicted to increase from USD 38.83 billion in 2025 to approximately USD 72.40 billion by 2034, expanding at a CAGR of 7.17% from 2025 to 2034. The increased prevalence of infectious diseases and advancements in vaccine technology are driving the global market. The government initiatives and support are further contributing to the market growth.
AI is playing a transformative role in the research and development of infectious disease vaccines. The ongoing focus on accelerating machine learning algorithms for creating vaccines for various disease to enhance their effectiveness and accessibility is contributing to the growth. AI acceleration in next-generation mRNA therapies for various infectious diseases is enabling the cutting-edge research and development of infectious disease vaccines. The ongoing focus on leveraging AI in infectious diseases for effective management and study of unknown patterns and sectors is supporting vaccine research & development.
The Asia Pacific infectious disease vaccines market size was exhibited at USD 12.61 billion in 2024 and is projected to be worth around USD 25.34 billion by 2034, growing at a CAGR of 7.23% from 2025 to 2034.
Asia Pacific Infectious Disease Vaccines Market
Asia Pacific dominates the global market, driven by the increased prevalence of infectious diseases in the region, particularly measles. The incidence of measles in East Asia and the Pacific has increased, driving significant focus on the vaccination program. The expanding pharmaceutical firms, investments in research & development, and government initiatives and support are contributing to the market growth. Government investments in local manufacturing capabilities in China and India are fostering the development and manufacturing of novel vaccines and therapeutics. The growing focus on technological advancements is further contributing to the market growth.
Asia Pacific is the hub for vaccine developments with 46% of the global prophylactic trials and 31% of therapeutic trials of vaccines, due to growing innovations in advanced technologies, strong pipelines, and collaborations to prevent compact disease. (Source: https://www.biospectrumasia.com)
Strong Manufacturing Capabilities: To Lead the China Market
China is a major player in the regional market, growth driven by the country's well-established pharmaceutical sector, robust research & development infrastructure, and government support. China leads the Asian vaccine market with 41% of prophylactic vaccine trials and 28% of therapeutic trials conducted. China dominates both prophylactic and therapeutic vaccine trials with advanced mRNA and viral vector platforms. China is a country with a large-scale prevalence of infectious diseases, driving significant emphasis on the development of vaccines to cope with part of the country's efforts to boost the areas of the manufacturing sector.
India as a Major Vaccine Supplier
India is the second-largest player in the regional market, contributing to the growth due to the country's vast vaccine manufacturing and strong supply of cost-effective vaccines. The government investments in local pharmaceutical companies and manufacturing giants are fostering this growth. According to the WHO vaccine report 2024, the WHO South-East Asia is the 87% self-supplier for its vaccines due with India 84% of doses procured in Asia and processing 99% of its needs. (Source: https://www.biospectrumasia.com)
North America Infectious Disease Vaccines Market
North America is the fastest-growing region in the global market, growth driven by the region’s large infectious disease prevalence and well-established healthcare infrastructure. North America is a large adopter of new vaccines and large-scale immunization programs for various diseases. The prevalence of infectious diseases such as seasonal influenza, COVID-19, and HPV is rapidly increasing in the region. The well-established healthcare system and government initiatives are supporting the market growth and vaccine distribution.
Large Infectious Disease Prevalence: To Boost the U.S. Vaccination Developments
The U.S. is a major player in the regional market, driven by robust regional healthcare infrastructure and the existence of robust pharmaceutical companies and regulatory support. The U.S. Food and Drug Administration (FDA) is accelerating approvals for novel and innovative vaccine developments and adoption for infectious diseases. The growing infectious disease cases in the U.S. is leading the focus on research, development, and manufacturing of novel and innovative vaccines.
The U.S. reported approximately 1,300 cases of measles in 2019, according to the Centers for Disease Control and Prevention (CDC). Between 2000 to 2024, 3 people died from measles in the U.S., where the number of cases led to 3 deaths by May 2025. (Source: https://www.chop.edu)
The infectious disease vaccines market refers to the industry focused on the research, development, production, and distribution of vaccines designed to prevent infectious diseases caused by viruses, bacteria, and other pathogens. This market includes traditional vaccine technologies as well as advanced platforms such as mRNA and vector-based vaccines, serving global immunization needs across age groups and geographies. Additionally, the advancements in new virus-like particle (VLP) platforms are further aiding in the creation of novel vaccine types and enhancing the effectiveness of existing ones.
The increased infectious disease prevalence has fueled the requirement for new trial designs and technology solutions to improve the speed and flexibility of infectious disease vaccine research and development. The government emphasizes preventing potential future risk of infectious diseases, and is contributing to rising investments in R&D and immunization programs.
CSL Seqirus UK Limited started manufacturing of over 5 million doses of the human H5 influenza vaccine in December 2024. The UK has bought these vaccines to protect against bird flu, in preparation to avoid risk in 2025. (Source: https://www.vax-before-travel.com)
| Report Coverage | Details |
| Market Size by 2034 | USD 72.40 Billion |
| Market Size in 2025 | USD 38.83 Billion |
| Market Size in 2024 | USD 36.25 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 7.17% |
| Dominating Region | Asia Pacific |
| Fastest Growing Region | North America |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Technology, Age Group,Disease Indication, Distribution Channel, End Use, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Technological Advancements in Vaccine Development and Administration
The technological advancements in vaccine development and administration, such as mRNA technology, self-amplifying RNA (saRNA) vaccines, vaccine delivery systems, digital health integration, and thermostable formulations, are driving the global market. The increased need for rapid development and scalability of infectious disease vaccines has led to the adoption of mRNA technologies. The ongoing demands for personalized vaccine administration have transformed focus toward advancements in genomics and biotechnology to enhance personalized vaccines and therapeutic vaccines for chronic infectious diseases, including hepatitis and HIV. The digital health integration includes electronic health records (EHRs), real-time adverse effect detection systems, and national immunization information registries and enhancing vaccine coverage and supply chain management.
High Vaccine Development and Manufacturing Cost
The high cost associated with the development and manufacturing of vaccines is the major market restraint. The development and manufacturing of vaccines includes various stages such as advanced research, multiple phases of preclinical and post clinical trials, and setting up a large-scale manufacturing process, adding to the cost. The strict quality control and regulatory compliance with safety and quality standards further add to this cost. The small pharmaceutical or low-resource setting-based firms witness high challenges for vaccine development and manufacturing.
Investments in Research & Development
Pharmaceutical companies, private organizations, and governments are investing heavily in R&D of vaccines to enhance novel developments and innovations. The investments are enabling developments of new and highly efficacy vaccines as well as advancements in vaccine technologies. The organization has invested heavily in major target vaccine developments for infectious diseases such as malaria, tuberculosis (TB), influenza, and HIV. Other diseases, like Group A Streptococcus, further contribute to research and development investments for urgent vaccines. The vaccine research and development investment cases are major identified by private pharmaceutical companies, multilateral donors, and national governments.
Which Technology Led the Infectious Disease Vaccines Market in 2024?
In 2024, the subunit, recombinant, polysaccharide & conjugate vaccines segment led the infectious disease vaccines market, due to their high specificity of pathogens like sugar antigens and proteins, hep to stimulate the immune system. The subunit and recombinant technology enable safe and targeted developments of vaccines to prevent the risk of disease-causing. The polysaccharide technology enables bacterial protection by targeting the sugar molecules. The conjugated vaccines technology helps to improve immune response, particularly in infants and young children.
The mRNA vaccines segment is expected to grow fastest over the forecast period, driven by its supportive role in the rapid development and scalability of effective vaccines. The regulatory approvals for novel mRNA vaccines are contributing to rising innovations and developments. The various preclinical and clinical trials for infectious disease vaccines have shown the effective role of mRNA vaccines. The growing technological advancements in mRNA vaccines for enhancing antiviral immunity against an infectious agent range, including varicella-zoster virus, rabies virus, CMV, RSV, HIV, influenza virus, Zika, and SARS-CoV-2, are supporting the segment growth.
What Made COVID-19 Disease Indication Dominate the Infectious Disease Vaccines Market in 2024?
The COVID-19 segment dominated the infectious disease vaccines market in 2024, due to rapid demand for effective vaccines for combating the pandemic 2024. The government funding for mass vaccination campaigns and growing awareness about the advantages of vaccination and prevention of healthcare measures contributed to the vaccine demand for the COVID-19 disease. The pandemic has shifted the government's focus on investing in vaccine development, manufacturing, and distribution. The rapid advancements in vaccine technologies, such as mRNA and viral vector vaccines, are bringing promising outcomes in offering immunity against COVID-19.
The dengue segment is the second-largest segment, leading the market, due to the increased prevalence of dengue in 2024. The government initiatives, such as the implementation of mass vaccination programs and collaborations with pharmaceutical companies for controlling dengue outbreaks, have boosted demand and adoption of the vaccines. The rising awareness about dengue and the importance of vaccination to prevent and control the disease are fostering the demand for vaccines. Additionally, the advancements in vaccine technologies like Sanofi’s Dengvaxia and Takada’s QDENGA are contributing to the segment’s growth.
Which Age Group Segment Dominates the Infectious Disease Market?
The pediatric segment dominated the infectious disease vaccines market in 2024, due to the high prevalence of infectious diseases in infants and children. The increased government and international support in immunization programs for pediatric vaccinations is fostering the high administration of vaccines in this age group. The prevalence of infectious diseases and transmissibility of diseases like MMR in children have high chances. The growing innovations in the development of new vaccines for the pediatric age group are forging the segment. Additionally, the growing combination vaccination rates are contributing to preventing infectious diseases in the pediatric age group.
The adult segment is the second-largest segment, leading the market, driven by increased demand for vaccines among adult patients. The impact of COVID-19 on the adult age group has fueled the awareness of the importance of preventing infectious diseases. The increased demand for vaccines to protect from age-related infectious diseases like the flu is further aiding in this growth. The large accessibility of effective vaccination for adults in pharmacies and hospitals is further supporting this growth.
What Made Government Immunization Programs Dominate the Infectious Disease Vaccines Market in 2024?
The government immunization programs segment dominated the market in 2024, due to increased government focus on preventing disease prevalence. Organizations, including Gavi, the Vaccine Alliance, and the World Health Organization (WHO), are accelerating to enhance vaccine access across the world. The immunization programs are the most effective and affordable interventions for eradicating diseases and controlling them. Immunization helps to save millions of patient lives across the world annually. It encourages healthcare providers, communities, and governments globally to increase their focus on vaccines and extended immunization coverage. The growing emphasis of government and organizations for investing in vaccine research & development, manufacturing, distribution, as well as increasing public awareness, is revolutionizing the market.
On November 10, the annual World Immunization Day is celebrated to increase awareness of the vaccine’s crucial role in the prevention of infectious diseases and public health protection. (Source: https://www.mohfw.gov.in)
The hospitals & clinics segment is expected to lead the market over the forecast period, driven by the rising adoption of vaccinations in hospitals & clinics. The hospitals & clinics are primary end-user providers of pediatric services, including vaccinations for children. The growing number of hospitalizations due to the increasing prevalence of infectious diseases is boosting the need for vaccinations in hospitals & clinics. Additionally, the participation of hospitals & clinics in immunization programs for offering essential vaccination services for patients is further contributing to the rising demand and adoption of infectious disease vaccines.
Which Distribution Channel Dominated the Infectious Disease Vaccines Market in 2024?
In 2024, the public (government & NGO-led programs) segment dominated the market, due to high adoption of vaccines through government and NGO-led programs. These programs are essential for providing access to vaccines in low-income countries. The growing emphasis of government and NGO-led programs to foster immunization coverage in underserved areas is fueling vaccine adoption. The global government initiatives like CEPI, WHO, and Gavi are accelerating development, manufacturing, and access to vaccine facilities.
The private (pharmacies, hospitals, clinics) segment is the fastest-growing segment of the market, and contributes to growth due to growing hospitalization and demand for effective vaccination in pharmacies, hospitals, and clinics. The hospitals and clinics are primary distributors of the vaccines. The growing awareness about the importance of vaccines has boosted demand for infectious disease therapies in hospitals and clinics. The pharmacies, hospitals, and clinics provide sophisticated patient care, prompt reimbursement, and favorable insurance policies, making vaccination more accessible for patients.
R&D
The R&D of infectious diseases includes stages such as exploratory, pre-clinical, and clinical developments in three phases of phase 1, phase 2, and phase 3, regulatory review & approvals, manufacturing, and pharmacovigilance
Key Players: Moderna, GSK, Sanofi, and Pfizer
Infectious disease vaccines go through pre-clinical trials, including phases 1, 2, 3, and 4. The regulatory frameworks, such as the U.S> Food and Drug Administration (FDA) and the European Medicines Agency (EMA), offer approvals for novel innovations and developments.
Key Players: Pfizer/BioNTech, GlaxoSmithKline (GSK), Moderna, and Merck & Co.
The typical packaging system for infectious vaccines is cardboard, shrink wraps, and plain boxes. Vials, ampoules, and prefillable syringes made from tubular glass or cyclo olefin polymer (COP) are mainly used in the packaging & serialization of vaccines.
Nepro is the major provider of high-quality primary packaging solutions for infectious disease vaccines, including D2FTM Pre-Fillable Glass Syringes and D2FTM Glass Vials.
(Source: https://www.nipro-group.com)
Key Players: SCHOTT AG, Stevanato Group, Gerresheimer AG, and Thermo Fisher Scientific.
By Technology
By Disease Indication
By Age Group
By End Use
By Distribution Channel
By Region
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
January 2025
August 2024
May 2025
October 2024